In the view of personalized treatment paradigms, CXCL10-targeted strategies promise to transform cancer immunotherapy by reprogramming the tumor microenvironment, overcoming resistance and achieving durable clinical responses. This evidence concerns the gene CXCL10 and neoplasm.